<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03829930</url>
  </required_header>
  <id_info>
    <org_study_id>GWCC 1000</org_study_id>
    <nct_id>NCT03829930</nct_id>
  </id_info>
  <brief_title>Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer</brief_title>
  <official_title>A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and tolerability of Entinostat in combination with Enzalutamide in
      metastatic castrate resistant prostate cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to determine the safety and tolerability of Entinostat with
      Enzalutamide for treatment of patients with castration-resistant prostate cancer. There will
      be two dose levels of Entinostat in combination with same dose of Enzalutamide. Patients will
      be followed during treatment and 1 month post discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3+3 Design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of a suitable dose of Entinostat in combination with Enzalutamide</measure>
    <time_frame>18 months</time_frame>
    <description>Number of participants who experience an adverse event assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants who survive without disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in circulating T cell subtype, peripheral blood mononuclear cell (PBMC) H3 acetylation, and phenotype of circulating Tregs</measure>
    <time_frame>18 months</time_frame>
    <description>Analysis of immunomodulatory effects of Entinostat</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Entinostat and Enzalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entinostat and Enzalutamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entinostat</intervention_name>
    <description>Entinostat is formulated for oral administration. A food effect is evident for entinostat; exposure is significantly reduced when entinostat is administered with a high fat meal. Accordingly, entinostat is to be administered on an empty stomach, at least 1 hour before and 2 hours after a meal. Entinostat tablets should not be split, crushed, or chewed. Consult the individual clinical protocols for specific dosing instructions.
Dose level 1: 3mg PO weekly. Dose level 2: 5mg PO weekly.</description>
    <arm_group_label>Entinostat and Enzalutamide</arm_group_label>
    <other_name>SYND-275 amd MS-275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Dose level 1: 160 mg PO daily. Dose level 2: 160 mg PO daily.</description>
    <arm_group_label>Entinostat and Enzalutamide</arm_group_label>
    <other_name>MDV3100</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each patient must meet all of the following inclusion criteria to be enrolled in the study:

          -  Age &gt;/= 18 years and are capable of giving informed consent. Voluntary written
             informed consent before performance of any study-related procedure not part of normal
             medical care, with the understanding that consent may be withdrawn by the subject at
             any time without prejudice to future medical care.

          -  Patients must have a pathologically confirmed diagnosis of prostate adenocarcinoma.
             Features of neuroendocrine phenotype are allowed.

          -  Patients must have evidence of castration resistant metastatic disease and eligible
             for Enzalutamide per standard guidelines. Castration resistant non-metastatic disease
             is allowed in phase I study if subject is candidate for Enzalutamide.

          -  Patients must have and ECOG performance status of ≤ 2.(appendix D)

          -  Patients must be on continuous LHRH agonist or antagonist treatment or surgically
             castrated with castrate levels of testosterone (&lt; 20 ng/dl).

          -  Any number of prior chemotherapy regimens are allowed. Chemotherapy naïve patients are
             allowed.

          -  If patient is already on Enzalutamide at a dose of 160mg daily, he is allowed if he
             can have baseline image and PSA within 1 month of the start of entinostat.

          -  Patients may have had androgen synthesis inhibitors or other investigational drugs.
             Patient must have discontinued flutamide or nilutamide or other AR targeted agents
             (including abiraterone) for at least 4 weeks and bicalutamide for at least 6 weeks
             prior to day 1 of treatment.

          -  Patients receiving treatment with bisphosphonates or denosumab must remain on
             treatment during the study.

          -  Patients must not require concurrent radiation or other chemotherapy while receiving
             protocol therapy. Patients may have received previous radiation but must have
             completed radiation at least 4 weeks (8 weeks for radiation to the brain) prior to
             registration.

          -  Patients must have recovered to grade ≤ 1 from all acute toxicity of previous
             radiation, hormonal or chemotherapy treatments.

          -  Patient agrees to use an acceptable method for contraception during the entire study
             treatment period through 4 months after the last dose of entinostat.

          -  Adequate renal function as defined by serum creatinine ≤ 1.5 x ULN. If creatinine &gt;1.5
             x ULN, calculated or measured creatinine clearance must be ≥ 60 mL/minute
             (Cockcroft-Gault).

          -  ANC &gt; 1500/mm³, platelets &gt; 100,000/mm³, Hgb &gt; 9 g/dL.

          -  Total bilirubin ≤ ULN, SGOT (AST) and SGPT (ALT)&lt; 1.5 x ULN. AST and/or ALT may be up
             to 5X ULN in the setting of known liver metastasis.

        Exclusion Criteria:

        Patients meeting any of the following exclusion criteria are not to be enrolled in the
        study:

          -  Patient was treated and discontinued Enzalutamide previously for any reason.

          -  Major surgery within 28 days or serious infection requiring IV antibiotics within 14
             days preceding the first dose of study treatment

          -  Patient has received other investigational drugs within 14 days before enrollment.

          -  Known GI disease or GI procedure that could impact drug absorption in the upper bowel,
             or tolerance of Entinostat. Examples include but are not limited to partial
             gastrectomy, small bowel resection, pancreatectomy, malabsorption or celiac disease

          -  Ongoing nausea or vomiting of any severity without improvement after appropriate
             treatment.

          -  &gt; Grade 1 diarrhea, not controlled with appropriate treatment.

          -  History of uncontrolled sleep apnea syndrome and other conditions that could result in
             excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease
             requiring supplemental oxygen.

          -  Clinical and/or radiographic evidence of cerebral metastases. However, patients who
             have a history of central nervous system (CNS) metastasis but who have no radiographic
             or clinical evidence of residual tumor (eg, following complete surgical resection or
             stereotactic radiosurgery) are not excluded from participation in this study.

          -  Myocardial infarction within 6 months prior to enrollment or has New York Heart
             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities. Prior to study entry, any EKG
             abnormality at Screening has to be documented by the investigator as not medically
             relevant.

          -  Serious medical or psychiatric illness or laboratory abnormality that may increase the
             risk associated with study participation or investigational product administration or
             may interfere with the interpretation of study results and, in the judgment of the
             investigator, would make the patient inappropriate for enrollment in this study.

          -  Any other currently active malignancy (excluding controlled non-melanoma skin cancer).
             Patients are considered NOT to have &quot;currently active&quot; malignancy if they have
             completed any necessary therapy and are considered by their physician to be at less
             than 30% risk of relapse.

          -  Treatment with clinically significant enzyme inducers, such as the enzyme-inducing
             antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin,
             rifapentine or St. John's Wort within 14 days prior to the first dose of Entinostat
             and during the study.

          -  History of seizure and on active therapy for seizure

          -  Known history of uncontrolled human immunodeficiency virus (HIV) infection. HIV
             positive patients will be allowed if they are on treatment and have an adequate CD4
             count (CD4 count &gt;200). Screening is not required in the absence of clinical findings
             or suspicion.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianquig Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brittany McNamara, BS</last_name>
    <phone>(202)994-0450</phone>
    <email>bmcnamara@mfa.gwu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>George Washington University - Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany McNamara, BS</last_name>
      <phone>202-994-0450</phone>
      <email>bmcnamara@mfa.gwu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/</url>
    <description>NCT00859472</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/</url>
    <description>NCT00878436</description>
  </link>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.</citation>
    <PMID>29313949</PMID>
  </reference>
  <reference>
    <citation>Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487.</citation>
    <PMID>18309951</PMID>
  </reference>
  <reference>
    <citation>D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):969-74.</citation>
    <PMID>9749478</PMID>
  </reference>
  <reference>
    <citation>Lytton B. Prostate cancer: a brief history and the discovery of hormonal ablation treatment. J Urol. 2001 Jun;165(6 Pt 1):1859-62.</citation>
    <PMID>11371867</PMID>
  </reference>
  <reference>
    <citation>Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C; Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):1-6. Review.</citation>
    <PMID>12231036</PMID>
  </reference>
  <reference>
    <citation>Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer. 1993 Dec 15;72(12 Suppl):3888-95.</citation>
    <PMID>8252511</PMID>
  </reference>
  <reference>
    <citation>Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002 May-Jun;52(3):154-79. Review.</citation>
    <PMID>12018929</PMID>
  </reference>
  <reference>
    <citation>Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7;351(15):1502-12.</citation>
    <PMID>15470213</PMID>
  </reference>
  <reference>
    <citation>de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.</citation>
    <PMID>20888992</PMID>
  </reference>
  <reference>
    <citation>Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.</citation>
    <PMID>20818862</PMID>
  </reference>
  <reference>
    <citation>Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 1;24(19):3089-94.</citation>
    <PMID>16809734</PMID>
  </reference>
  <reference>
    <citation>de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.</citation>
    <PMID>21612468</PMID>
  </reference>
  <reference>
    <citation>Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009 Aug 1;15(15):4792-8. doi: 10.1158/1078-0432.CCR-08-2660. Epub 2009 Jul 28. Review.</citation>
    <PMID>19638458</PMID>
  </reference>
  <reference>
    <citation>Nelson PS. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol. 2012 Feb 20;30(6):644-6. doi: 10.1200/JCO.2011.39.1300. Epub 2011 Dec 19.</citation>
    <PMID>22184375</PMID>
  </reference>
  <reference>
    <citation>Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9.</citation>
    <PMID>19359544</PMID>
  </reference>
  <reference>
    <citation>Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.</citation>
    <PMID>22894553</PMID>
  </reference>
  <reference>
    <citation>Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Oct 30;371(18):1755-6. doi: 10.1056/NEJMc1410239.</citation>
    <PMID>25354111</PMID>
  </reference>
  <reference>
    <citation>Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3.</citation>
    <PMID>25184630</PMID>
  </reference>
  <reference>
    <citation>Lin J, Wang C, Kelly WK. Targeting epigenetics for the treatment of prostate cancer: recent progress and future directions. Semin Oncol. 2013 Jun;40(3):393-401. doi: 10.1053/j.seminoncol.2013.04.010.</citation>
    <PMID>23806502</PMID>
  </reference>
  <reference>
    <citation>Kaushik D, Vashistha V, Isharwal S, Sediqe SA, Lin MF. Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. Ther Adv Urol. 2015 Dec;7(6):388-95. doi: 10.1177/1756287215597637. Review.</citation>
    <PMID>26622323</PMID>
  </reference>
  <reference>
    <citation>Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget. 2016 Feb 16;7(7):7390-402. doi: 10.18632/oncotarget.7180.</citation>
    <PMID>26862729</PMID>
  </reference>
  <reference>
    <citation>Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res. 2001 Aug;7(8):2292-300.</citation>
    <PMID>11489804</PMID>
  </reference>
  <reference>
    <citation>Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM, Hu J, Dzik-Jurasz A, Yang W, Scher HI. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2010 May;66(1):181-9. doi: 10.1007/s00280-010-1289-x. Epub 2010 Mar 9.</citation>
    <PMID>20217089</PMID>
  </reference>
  <reference>
    <citation>Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7.</citation>
    <PMID>10200307</PMID>
  </reference>
  <reference>
    <citation>Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn PA Jr, Hirsch FR. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol. 2012 Jun 20;30(18):2248-55. doi: 10.1200/JCO.2011.38.9411. Epub 2012 Apr 16.</citation>
    <PMID>22508830</PMID>
  </reference>
  <reference>
    <citation>Gore SD, Jiemjit A, Silverman LB, et al. Combined methyltransferase/histone deacetylase inhibition with 5-azacitidine and MS-275 in patients with MDS, CMMoL and AML: Clinical response, histone acetylation and DNA damage. Blood 2006; 108: Abstract 517</citation>
  </reference>
  <reference>
    <citation>Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, Trepel JB. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013 Jun 10;31(17):2128-35. doi: 10.1200/JCO.2012.43.7251. Epub 2013 May 6.</citation>
    <PMID>23650416</PMID>
  </reference>
  <reference>
    <citation>Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One. 2012;7(1):e30815. doi: 10.1371/journal.pone.0030815. Epub 2012 Jan 27.</citation>
    <PMID>22303460</PMID>
  </reference>
  <reference>
    <citation>Kato Y, Yoshino I, Egusa C, Maeda T, Pili R, Tsuboi R. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells. J Dermatol Sci. 2014 Aug;75(2):140-7. doi: 10.1016/j.jdermsci.2014.04.014. Epub 2014 May 14.</citation>
    <PMID>24866536</PMID>
  </reference>
  <reference>
    <citation>Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer. 2012 Jan 3;106(1):77-84. doi: 10.1038/bjc.2011.527. Epub 2011 Dec 1.</citation>
    <PMID>22134508</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 26, 2019</study_first_submitted>
  <study_first_submitted_qc>February 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Jianqing Lin</investigator_full_name>
    <investigator_title>Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>Castration resistant prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

